Cargando…

Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol

INTRODUCTION: Empagliflozin is an SGLT-2 inhibitor (SGLT-2i) which belongs to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose independently from insulin, through an increase in glycosuria. In addition to decreasing cardiovascular morbidity and mortality, empagl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muller, Marie-Eve, Pruijm, Menno, Bonny, Olivier, Burnier, Michel, Zanchi, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015115/ https://www.ncbi.nlm.nih.gov/pubmed/29802538 http://dx.doi.org/10.1007/s12325-018-0708-y

Ejemplares similares

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
por: Zanchi, Anne, et al.
Publicado: (2020)

Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects
por: Zanchi, Anne, et al.
Publicado: (2022)

Blood Oxygenation Level-Dependent MRI to Assess Renal Oxygenation in Renal Diseases: Progresses and Challenges
por: Pruijm, Menno, et al.
Publicado: (2017)

Renal Tissue Oxygenation in Essential Hypertension and Chronic Kidney Disease
por: Pruijm, Menno, et al.
Publicado: (2013)

Blood pressure and vascular determinants of glomerular filtration rate decline in diabetic kidney disease
por: Truscello, Luca, et al.
Publicado: (2023)

Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)
por: Bandiera, Carole, et al.
Publicado: (2021)

Determinants of Renal Tissue Oxygenation as Measured with BOLD-MRI in Chronic Kidney Disease and Hypertension in Humans
por: Pruijm, Menno, et al.
Publicado: (2014)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design
por: Fujiki, Shinya, et al.
Publicado: (2020)

Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
por: Ferreira, Antonio, et al.
Publicado: (2022)

Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine
por: Pruijm, Menno T, et al.
Publicado: (2008)

Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial
por: Schietzel, Simeon, et al.
Publicado: (2022)

OR27-6 Effects of the SGLT2-Inhibitor Empagliflozin in Patients With Chronic Syndrome of Inadequate Antidiuresis (SIAD) - Results of a Double-Blind, Randomized, Placebo-Controlled, Crossover Trial
por: Berres, Manfred, et al.
Publicado: (2022)

Long-term use and tolerability of irbesartan for control of hypertension
por: Forni, Valentina, et al.
Publicado: (2011)

Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA
por: Caroli, Anna, et al.
Publicado: (2018)

Letter Regarding “Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis”
por: Halfon, Matthieu, et al.
Publicado: (2022)

Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review
por: Pruijm, Menno, et al.
Publicado: (2018)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya
por: Smit, Menno R, et al.
Publicado: (2016)

The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study
por: Chinna Meyyappan, Arthi, et al.
Publicado: (2021)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial
por: Dhayat, Nasser A., et al.
Publicado: (2018)

Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
por: Forni Ogna, Valentina, et al.
Publicado: (2013)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
por: Hijikata, Yasuhiro, et al.
Publicado: (2018)

Statin treatment for unruptured intracranial aneurysms study: a study protocol for a double-blind, placebo-controlled trial
por: Li, Wenqiang, et al.
Publicado: (2020)

Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial
por: Fayoux, Pierre, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
por: Sone, Hirohito, et al.
Publicado: (2019)

Determinants of Renal Micro-Perfusion as Assessed with Contrast-Enhanced Ultrasound in Healthy Males and Females
por: Ulpiano Trillig, Antonio, et al.
Publicado: (2023)

The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial
por: de Jonghe, Annemarieke, et al.
Publicado: (2011)

Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
por: Martorina, Wagner, et al.
Publicado: (2023)

Effect of Kami Guibi-tang (KGT) in elderly subjects with insomnia: a study protocol from a single center, randomized, double-blind, placebo-controlled trial
por: Lee, Kyeong-Hwa, et al.
Publicado: (2023)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o1bn8e0ri0r1sincfudt3emo0l